Pfizer settles patent litigation regarding Teva's generic Neurontin

05/31/2011 | Bloomberg

Pfizer reached a settlement with Teva Pharmaceutical Industries that lets the latter continue marketing a generic version of epilepsy medicine Neurontin. Pfizer had said generic Neurontin sold by Teva and its unit Ivax, as well as Actavis Group subsidiary Purepac, infringes a key patent that lasts until 2017.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health